Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial
在复发型多发性硬化症患者中,改用芬戈莫德与继续使用醋酸格拉替雷或β干扰素相比,对患者和医生报告结局的影响:EPOC试验的事后分析
期刊:BMC Neurology
影响因子:2.2
doi:10.1186/s12883-014-0220-1
Calkwood, Jonathan; Cree, Bruce; Crayton, Heidi; Kantor, Daniel; Steingo, Brian; Barbato, Luigi; Hashmonay, Ron; Agashivala, Neetu; McCague, Kevin; Tenenbaum, Nadia; Edwards, Keith